{"id":"ab-pa01","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T18:00:42.599379","_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AB-PA01 is a phage-based therapeutic designed to selectively infect and destroy Pseudomonas aeruginosa, a multidrug-resistant pathogen. The bacteriophage approach offers an alternative to conventional antibiotics by using naturally occurring viruses that specifically target bacterial cells, potentially reducing the development of antibiotic resistance.","oneSentence":"AB-PA01 is a bacteriophage therapeutic that targets and lyses pathogenic bacteria to treat infections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:08.383Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic Pseudomonas aeruginosa respiratory tract infections in cystic fibrosis patients"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT03395743","phase":"","title":"Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic","status":"NO_LONGER_AVAILABLE","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"","conditions":"","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2024 Feb 12","pmid":"38347019","title":"Lytic activity of phages against bacterial pathogens infecting diabetic foot ulcers.","journal":"Scientific reports"},{"date":"2020 May 18","pmid":"32443619","title":"Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms.","journal":"Viruses"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AB-PA01","genericName":"AB-PA01","companyName":"Armata Pharmaceuticals, Inc.","companyId":"armata-pharmaceuticals-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"AB-PA01 is a bacteriophage therapeutic that targets and lyses pathogenic bacteria to treat infections. Used for Chronic Pseudomonas aeruginosa respiratory tract infections in cystic fibrosis patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}